Werewolf Therapeutics Inc (HOWL)
5.17
-0.19
(-3.54%)
USD |
NASDAQ |
May 31, 16:00
5.165
0.00 (0.00%)
After-Hours: 20:00
Werewolf Therapeutics EPS Diluted (Quarterly): -0.39 for March 31, 2024
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -0.39 |
December 31, 2023 | -0.33 |
September 30, 2023 | -0.23 |
June 30, 2023 | -0.14 |
March 31, 2023 | -0.34 |
December 31, 2022 | -0.39 |
September 30, 2022 | -0.40 |
June 30, 2022 | -0.53 |
March 31, 2022 | -0.56 |
Date | Value |
---|---|
December 31, 2021 | -0.66 |
September 30, 2021 | -0.51 |
June 30, 2021 | -3.82 |
March 31, 2021 | -3.897 |
December 31, 2020 | -2.291 |
September 30, 2020 | -0.6764 |
June 30, 2020 | 0.2481 |
March 31, 2020 | -0.4266 |
Earnings per Share Definition
Earnings per share measures the total net income / average shares outstanding during income period. There are a few variations to earnings per share that are listed including "EPS Basic", "EPS Diluted", "Normalized Basic EPS", and "Normalized Diluted EPS". Each of these metrics are dependent on which earnings and shares outstanding metrics are used. Basic and Diluted EPS differ in that diluted shares are the amount of shares outstanding after all convertible securities, options, and warrants are exercised. Normalized EPS allows does not include one-time expenses.
EPS Diluted (Quarterly) Range, Past 5 Years
-3.897
Minimum
Mar 2021
0.2481
Maximum
Jun 2020
-0.9025
Average
-0.4266
Median
Mar 2020
EPS Diluted (Quarterly) Benchmarks
CEL-SCI Corp | -0.14 |
AIM ImmunoTech Inc | -0.12 |
IGC Pharma Inc | -0.09 |
NovaBay Pharmaceuticals Inc | -5.25 |
Protalix BioTherapeutics Inc | -0.06 |
EPS Diluted (Quarterly) Related Metrics
Net Income (Quarterly) | -16.19M |
Revenue (Quarterly) | 0.742M |
Total Expenses (Quarterly) | 17.90M |
Enterprise Value | 124.89M |
Profit Margin (Quarterly) | -2.18K% |
Earnings Yield | -21.08% |
Normalized Earnings Yield | -21.08 |